Add-on Acquisition • Life Science

Clade Therapeutics Acquires Gadeta

On October 2, 2023, Clade Therapeutics acquired life science company Gadeta

Acquisition Context

This is Clade Therapeutics’ 1st transaction in the Life Science sector.
This is Clade Therapeutics’ 1st transaction in the Netherlands.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	October 2, 2023
Target	Gadeta
Sector	Life Science
Buyer(s)	Clade Therapeutics
Deal Type	Add-on Acquisition

Target Company

Gadeta

Utrecht, Netherlands

Gadeta is a cell therapy company developing innovative treatments based on g/d T cell receptors for targeting solid tumors. The company's platform is focused on discovering and developing novel g/d T cell receptors (TCRs) that can specifically recognize novel cancer-specific surface targets. Gadeta was formed in 2015 and is based in Utrecht, Netherlands.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Clade Therapeutics

Boston, Massachusetts, United States

Category	Company
Sector	Life Science

DESCRIPTION

Clade Therapeutics is a biopharmaceutical company focused on discovering and delivering engineerable, off-the-shelf, scalable, and consistent stem cell-based medicines. The company provides a robust cellular platform with stem-cell-derived immune cells for the treatment of cancer and autoimmune diseases. Clade Therapeutics is based in Boston, Massachusetts.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
Country: Netherlands	1 of 1
Year: 2023	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Netherlands M&A - 2023 M&A